IGF-1 analog peptide
IGF-1 DES
IGF-1 DES is des(1-3)IGF-I, an IGF-I variant that lacks the tripeptide Gly-Pro-Glu at its N-terminus, and the work on it that the sources describe was done in cells and animals.1
IGF-1 DES after one dose: 50% at ~0.3 h, 25% at 0.6 h, 12.5% at 0.9 h.
Drawn from the half-life in the app's model, ~0.3 h. The model's figures
- Compound
- IGF-1 DES
- Symbol
- DES
- Family
- Growth hormone peptides
- Parts
- 13
- References
- 7
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Des(1-3)IGF-I is a truncated variant of human IGF-I with the tripeptide Gly-Pro-Glu absent from the N-terminus, according to a 1996 review by Ballard and colleagues of the Cooperative Research Centre for Tissue Growth and Repair, Adelaide, in the International Journal of Biochemistry and Cell Biology.1 The review says the protein "has been isolated from bovine colostrum, human brain and porcine uterus" and "probably results from post-translational cleavage of IGF-I".1 The same review states that "Clinical opportunities for des(1-3)IGF-I have not yet been evaluated".1 Mongongu and colleagues (Agence Française de Lutte contre le Dopage, Drug Testing and Analysis, 2021) write that IGF-I and its analogs, Des(1-3)-IGF-I among them, "were never approved for use in humans" and "are readily available as black market products for bodybuilding".2 The app grades the evidence for IGF-1 DES as emerging, lists the route as subcutaneous, and its notes describe use in bodybuilding by injection at the site of the muscle.
How it works
Sources in this part
The app's notes describe reduced affinity for IGF-binding proteins, giving roughly 10 times greater local potency. Ballard and colleagues' review reports that des(1-3)IGF-I "generally is about 10-fold more potent than IGF-I at stimulating hypertrophy and proliferation of cultured cells", a result of "much reduced binding to IGF-binding proteins" that the review traces to the absence of the glutamate at position 3.1 The 10-fold figure is for cultured cells; the review adds that the increased potency "is retained in part when the variant is administered in vivo", with selective anabolic effects "particularly evident in gut tissues".1 Ross and colleagues (CSIRO Division of Human Nutrition, Adelaide, Biochemical Journal, 1989) tested a binding protein purified from bovine kidney cells in chick embryo fibroblasts and reported that it "did not influence the biological activities of des-(1-3)-IGF-1, while effects on IGF-1 were intermediate".3 They conclude that the enhanced potency "is a consequence of it not binding to purified binding proteins or those released by cultured cells".3 These are cell results; the paper does not test people. Ballard and colleagues (Journal of Endocrinology, 1991) added labelled peptides to rat plasma and reported that binding-protein association "was greater with labelled IGF-II and essentially absent with the truncated IGF-I analogue, des(1-3)IGF-I".4 After injection into rats, "most of the des(1-3)IGF-I radioactivity remained free".4
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~0.3 h
- Bioavailability
- 95%
- Typical dose
- 50–150 mcg/day
- Route
- SubQ
- Time to peak
- ~0.25 h
Sources in this part
The second column holds the app's figures; the third holds what the cited papers report, all of it from rats.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~0.3 h | No half-life figure in people or animals appears in the records read for the cited papers; the rat plasma clearance of des(1-3)IGF-I was 4.59 ml/min per kg against 1.20 for IGF-I and 1.34 for IGF-II4 |
| Volume of distribution | Not given in the app | In rats, the mean steady-state volume of distribution was 461 ml/kg for des(1-3)IGF-I, 167 for IGF-I and 181 for IGF-II4 |
| Bioavailability | 95% | No bioavailability figure for des(1-3)IGF-I appears in the records read for the cited papers |
| Time to peak | ~0.25 h | No time-to-peak figure appears in the records read for the cited papers |
| Detection after injection | Not given in the app | In rats given 100 μg/kg intramuscularly, unchanged Des(1-3)-IGF-I was detected until 24 h after administration, with detection evaluated up to 36 h2 |
The authors of the 1991 clearance study interpret the faster clearance this way: "we suggest that IGF analogues that are cleared rapidly from blood may have greater biological potencies in vivo".4 The app lists a duration of 4 hours; the records read for the cited papers give no matching figure.
Human studies
No controlled trial of des(1-3)IGF-I in people was identified in PubMed (a search for des(1-3)IGF-I returned 106 records, and a search adding "clinical trial human administration" returned none) or in ClinicalTrials.gov (none of the 20 listed records for "IGF-1 des(1-3)" concerned this compound). A search of DailyMed labels for the same name returned no labels. These searches support only that nothing was identified in those three databases on that date.
Laboratory and animal studies
The table lists the studies cited here. Every row is from cells or rats, not people.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Ross and colleagues, Biochemical Journal 19893 | Cell study with binding proteins from bovine kidney cells and human amniotic fluid | None; chick embryo fibroblasts and L6 myoblasts | Not given in the PubMed record | The bovine binding protein did not influence des-(1-3)-IGF-1 activity, while effects on IGF-1 were intermediate; potency of the three peptides correlated inversely with binding |
| Ballard and colleagues, Journal of Endocrinology 19914 | Labelled IGF-I, IGF-II and des(1-3)IGF-I in rat plasma and after intravenous injection | None; rats, number not given in the record | Tracer doses and length not given in the record | Clearance 4.59 ml/min per kg for des(1-3)IGF-I against 1.20 (IGF-I) and 1.34 (IGF-II); kidneys held more radioactivity than other organs with all tracers |
| Martin and colleagues, American Journal of Physiology 19915 | Subtotally nephrectomized rats given IGF-I at two doses or des-(1-3)IGF-I | None; young male rats, number not given in the record | Des-(1-3)IGF-I 0.9 mg per kg per day by osmotic minipump for 7 days | Body weight gain, food utilization and nitrogen balance were significantly increased with des-(1-3)IGF-I; carcass composition was not affected by IGF treatment |
| Tomas and colleagues, Biochemical Journal 19916 | Streptozotocin-induced diabetic rats infused with hGH, IGF-I, des(1-3)IGF-I or insulin | None; diabetic rats, number not given in the record | Des(1-3)IGF-I 1.08 mg/kg per day, infused for 7 days | Body weight gain and nitrogen retention with des(1-3)IGF-I were approx. 70% of the improvement obtained with insulin at 25 or 30 units/kg per day; IGF-I at 1.05 or 1.08 mg/kg per day gave about 30%, significant only in the second experiment; the IGF peptides did not ameliorate the diabetic glucosuria |
| Mongongu and colleagues, Drug Testing and Analysis 20212 | Method validation, then a single-injection study in rats | None; rats; human serum spiked for assay validation | 100 μg/kg intramuscularly, once; detection followed to 36 h | Unchanged Des(1-3)-IGF-I was detected until 24 h after administration |
Deeper analysis: plasma clearance and tissue distribution in rats
Ballard and colleagues (CSIRO Division of Human Nutrition, Adelaide) published the study in the Journal of Endocrinology in 1991, and the record lists no grant or sponsor.4 The design compared 125I-labelled IGF-I, IGF-II and des(1-3)IGF-I, first in rat plasma at 4 degrees C and then after intravenous injection of the tracers into rats.4 Des(1-3)IGF-I was cleared faster (4.59 ml/min per kg against 1.20 and 1.34) and had a larger steady-state volume of distribution (461 ml/kg against 167 and 181).4 The authors attribute the larger volume "probably" to "the differences in plasma protein binding".4 Radioactivity in the adrenals, brain, skin, stomach, duodenum, ileum plus jejunum and colon ranked des(1-3)IGF-I greater than IGF-I greater than IGF-II, which the authors say is the opposite of the ranking for binding to plasma proteins.4 The record gives no animal numbers and does not list the authors' limitations, and the findings are about a radiolabel in rats, not about effects in people.4
Deeper analysis: diabetic and nephrectomized rats
Tomas and colleagues (Biochemical Journal, 1991) infused hGH, IGF-I, des(1-3)IGF-I and insulin for 7 days in streptozotocin-induced diabetic rats.6 IGF-I at 1.05 or 1.08 mg/kg per day raised body weight and nitrogen retention to about 30% of the insulin improvement, with statistical significance only in the second of two experiments; a 2.5-fold higher IGF-I dose or des(1-3)IGF-I at 1.08 mg/kg per day gave about 70%, and hGH at 1.38 mg/kg per day "was not effective".6 Secondary results: muscle protein breakdown, assessed by 3-methylhistidine excretion, "was inhibited by insulin, but not by the IGF peptides", carcass fat increased with insulin but not with the IGF peptides, and des(1-3)IGF-I "induced binding proteins, but had only a slight effect on measured IGF-I concentrations".6 The authors conclude that "des(1-3)IGF-I is at least as potent as the full-length IGF-I" and that the IGF peptides improve nitrogen balance in diabetes "without obviously influencing the abnormal carbohydrate metabolism".6 The affiliation is the CSIRO Division of Human Nutrition, Adelaide; the record lists no grant or sponsor and states no limitations.6 Martin and colleagues (American Journal of Physiology, 1991; Child Health Research Institute, Adelaide) gave des-(1-3)IGF-I to rats with reduced renal mass and reported a reduced urinary excretion rate of 3-methylhistidine, which they say may partly explain the improved nitrogen balance.5 That finding differs from the diabetic-rat result above, where the IGF peptides did not inhibit muscle protein breakdown, and the two models, doses and groups differ.6,5 The PubMed record of Martin and colleagues is marked "Research Support, Non-U.S. Gov't" and lists no named sponsor.5
Doses reported in studies and on labels
The sources give no label dose for des(1-3)IGF-I and no dose used in people. The table lists the app's figure beside the animal doses reported in the cited papers.
| Source | Subject and route | Dose and length | Comparator |
|---|---|---|---|
| App's figure | Route: subcutaneous | 50–150 mcg/day | Not applicable |
| Martin and colleagues 19915 | Subtotally nephrectomized young male rats; osmotic minipump | 0.9 mg per kg body weight per day for 7 days | IGF-I at 0.9 and 2.2 mg per kg per day |
| Tomas and colleagues 19916 | Streptozotocin-induced diabetic rats; infusion | 1.08 mg/kg per day for 7 days | IGF-I 1.05 or 1.08 mg/kg per day, and a 2.5-fold higher IGF-I dose; hGH; insulin |
| Mongongu and colleagues 20212 | Rats; single intramuscular injection | 100 μg/kg once | Other IGF-I analogs in the same study |
Sources in this part
Bloodwork and markers
Sources in this part
The app lists IGF-1 as the marker to monitor for IGF-1 DES. In diabetic rats, des(1-3)IGF-I "had only a slight effect on measured IGF-I concentrations" while inducing binding proteins, whereas IGF-I increased IGF-I concentrations and IGF-I-binding proteins in plasma, especially at the higher dose.6 No paper cited here reports IGF-I concentrations after des(1-3)IGF-I in people.
Regulatory and anti-doping status
Sources in this part
The World Anti-Doping Agency's 2026 Prohibited List names "Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues" under S2.3, growth factors and growth factor modulators.7 The S2 class is listed as prohibited at all times, in and out of competition.7 The list does not name des(1-3)IGF-I; the entry reads "Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues", under the heading "Including, but not limited to".7 Mongongu and colleagues state that IGF-I and its analogs, including Des(1-3)-IGF-I, "are prohibited substances in sport", and that they "were never approved for use in humans".2 The same group validated a method using immunopurification and high resolution mass spectrometry; the record lists a grant from the Agence Française de Lutte contre le Dopage, where four of the six authors work.2 They also report "Abundant signs of lower quality, oxidized peptide forms" in black market products, which they say justifies monitoring "at least both the native and mono-oxidized forms".2 The authors write that the same degradation products, which they report for LongR3-IGF-I, were found after in vitro incubation of the analogs in human whole blood, "suggesting that observations in rats may be extrapolated to humans"; this is a suggestion in the record and not a human administration study.2
What is not known
Sources in this part
The app's notes say there is "little human safety data" and describe theoretical IGF-1 agonist risks, namely hypoglycemia and mitogenic concerns. None of the cited papers measures hypoglycemia or tumour growth after des(1-3)IGF-I in people, and the human data the app's figures rest on are not identified in the records read. A 1996 review states that clinical opportunities for the variant "have not yet been evaluated".1 The half-life, bioavailability, time to peak, duration and dose range in the app have no matching figure in the records read for the cited papers. The rat studies used doses in mg per kg and several routes, so none maps onto the app's mcg per day range.
Frequently asked questions
What is IGF-1 DES?
IGF-1 DES is des(1-3)IGF-I, a truncated variant of human IGF-I with the tripeptide Gly-Pro-Glu absent from the N-terminus.1
What is the half-life of IGF-1 DES?
The app lists a half-life of about 0.3 hours, and no half-life figure appears in the records read for the papers cited here. In rats, the plasma clearance of des(1-3)IGF-I was 4.59 ml/min per kg against 1.20 for IGF-I.4
Is IGF-1 DES banned by WADA?
Is IGF-1 DES approved for human use?
Mongongu and colleagues state that IGF-I and its analogs, Des(1-3)-IGF-I among them, were never approved for use in humans.2 A DailyMed search on 16 November 2026 returned no label for the name.
Has IGF-1 DES been tested in people?
No controlled trial in people was identified in PubMed or ClinicalTrials.gov. A 1996 review states that clinical opportunities for the variant have not yet been evaluated.1
How is IGF-1 DES different from IGF-1?
Does IGF-1 DES bind IGF-binding proteins?
Ross and colleagues report that a purified binding protein did not influence the activity of des-(1-3)-IGF-1 in chick embryo fibroblasts.3 In rat plasma incubated at 4 degrees C, binding-protein association was essentially absent for des(1-3)IGF-I; after intravenous injection into rats a greater degree of binding occurred, but most of the des(1-3)IGF-I radioactivity remained free.4
Guides, tools and comparisons
References
- Ballard FJ, et al. Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I. Int J Biochem Cell Biol 1996. PMID 8930132
- Mongongu C, et al. Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes. Drug Test Anal 2021. PMID 33587816
- Ross M, et al. Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1. Biochem J 1989. PMC1138350
- Ballard FJ, et al. Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I in rats. J Endocrinol 1991. PMID 2005410
- Martin AA, et al. IGF-I and its variant, des-(1-3)IGF-I, enhance growth in rats with reduced renal mass. Am J Physiol 1991. PMID 1928375
- Tomas FM, et al. Increased weight gain, nitrogen retention and muscle protein synthesis following treatment of diabetic rats with insulin-like growth factor (IGF)-I and des(1-3)IGF-I. Biochem J 1991. PMC1151126
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list